<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862081</url>
  </required_header>
  <id_info>
    <org_study_id>GO27802</org_study_id>
    <secondary_id>2013-003543-28</secondary_id>
    <nct_id>NCT01862081</nct_id>
  </id_info>
  <brief_title>A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, dose-escalation study designed to assess the safety,
      tolerability, and pharmacokinetics of oral GDC-0032 administered in combination with either
      docetaxel or with paclitaxel. Patients treated with the GDC-0032 and docetaxel have
      HER2-negative locally recurrent or metastatic breast cancer or non-small cell lung cancer
      (NSCLC). Patients treated with the GDC-0032 and paclitaxel combination have human epidermal
      growth factor receptor 2 (HER2)-negative locally recurrent or metastatic breast cancer.
      There are two potential stages within each arm of this study: a dose-escalation stage (Stage
      1) and a dose-expansion stage (Stage 2). Once the maximum tolerated dose of GDC-0032 in a
      given arm has been established from dose escalation, additional patients with each
      combination will be enrolled in Stage 2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of dose limiting toxicities</measure>
    <time_frame>Up to 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time 0 to the last measurable concentration (AUC0-last)</measure>
    <time_frame>Up to 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed plasma concentration (Cmin)</measure>
    <time_frame>Up to 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response according to RECIST v1.1</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response according to RECIST v1.1</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) according to RECIST v1.1</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Breast Cancer, Non-small Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GDC-0032 once daily for 21 consecutive days (beginning from Day 1) in each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: GDC-0032 + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GDC-0032 once daily for 28 consecutive days (beginning from Day 1) in each 28-day cycle along with Paclitaxel on Days 1, 8, 15 and 22 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GDC-0032 once daily on Day 1 and Days 8-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GDC-0032 once daily on Days 2-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GDC-0032 once daily on Days 1-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F: GDC-0032 + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GDC-0032 once daily on a 5-days on, 2-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G: GDC-0032 + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GDC-0032 once daily on a 3-days on, 4-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Participants will receive docetaxel 75 milligrams per meter-squared (mg/m^2) intravenous (IV) dose on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Arm A: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_label>Arm C: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_label>Arm D: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_label>Arm E: GDC-0032 + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0032</intervention_name>
    <description>Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.</description>
    <arm_group_label>Arm A: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_label>Arm B: GDC-0032 + Paclitaxel</arm_group_label>
    <arm_group_label>Arm C: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_label>Arm D: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_label>Arm E: GDC-0032 + Docetaxel</arm_group_label>
    <arm_group_label>Arm F: GDC-0032 + Paclitaxel</arm_group_label>
    <arm_group_label>Arm G: GDC-0032 + Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Participants will receive paclitaxel 80 mg/m^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.</description>
    <arm_group_label>Arm B: GDC-0032 + Paclitaxel</arm_group_label>
    <arm_group_label>Arm F: GDC-0032 + Paclitaxel</arm_group_label>
    <arm_group_label>Arm G: GDC-0032 + Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years

          -  For paclitaxel combination arms: histologically or cytologically documented
             adenocarcinoma of the breast with locally recurrent or metastatic disease

          -  For docetaxel combination arms: histologically or cytologically documented
             adenocarcinoma of the breast with locally recurrent or metastatic disease or
             histologically documented advanced (Stage IV) or recurrent NSCLC

          -  For participants with breast cancer: HER2-negative disease as defined by local
             clinical guidelines

          -  Participants with NSCLC to be treated with docetaxel need to have received at least
             one prior anti-cancer treatment regimen in an advanced setting and to have docetaxel
             be considered appropriate treatment

          -  Evaluable or measurable disease per response evaluation criteria in solid tumors
             (RECIST) v.1.1

          -  Life expectancy &gt;=12 weeks

          -  Eastern cooperative oncology group (ECOG) performance status of 0 or 1 at screening

          -  Adequate hematologic and end organ function

          -  Use of highly effective form of contraception

        Exclusion Criteria:

          -  Prior anti-cancer therapy

          -  Prior treatment with phosphoinositide 3-kinase (PI3K) inhibitor

          -  Known significant hypersensitivity to any components of study treatment

          -  Grade &gt;=2 peripheral neuropathy

          -  Type 1 or Type 2 diabetes

          -  Grade &gt;=2 hypercholesterolemia or hypertriglyceridemia

          -  Congenital long QT syndrome

          -  Active congestive heart failure or ventricular arrhythmia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO27802 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4X 1K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 1, 2015</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
